e-learning
resources
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Immunotherapy in severe asthma
A. Bossios (Stockholm, Sweden), W. Canonica (Milan, Italy), C. Porsbjerg (Copenhagen, Denmark)
Source:
ERS webinar 2021: Immunotherapy in severe asthma
Number:
0
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Bossios (Stockholm, Sweden), W. Canonica (Milan, Italy), C. Porsbjerg (Copenhagen, Denmark). Immunotherapy in severe asthma. ERS webinar 2021: Immunotherapy in severe asthma
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Refining asthma treatment for mild asthma
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma
Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma
Year: 2019
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Anti-IgE treatment: An alternative for severe allergic occupational asthma
Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors?
Year: 2012
Immunotherapy prevents the development of asthma in subjects with allergic rhinitis
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001
Difficult to treat asthma
Source: Annual Congress 2006 - Clinical year in review
Year: 2006
Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011
Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma
Source: Eur Respir J 2002; 19: 846-852
Year: 2002
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Year: 2021
Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept